This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Kitasamycin
Accession Number
DB09309
Type
Small Molecule
Groups
Experimental
Description

Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis.

Structure
Thumb
Synonyms
  • Leucomycin
Product Ingredients
IngredientUNIICASInChI Key
Kitasamycin tartrateIPN75MD9DR37280-56-1LCDBILLRZFJKMN-RKYMYSRXSA-N
Categories
UNII
YX09Z4QW5Y
CAS number
1392-21-8
Weight
Average: 785.969
Monoisotopic: 785.456155841
Chemical Formula
C40H67NO14
InChI Key
IEMDOFXTVAPVLX-YWQHLDGFSA-N
InChI
InChI=1S/C40H67NO14/c1-22(2)18-30(45)53-38-26(6)51-32(21-40(38,7)48)54-35-25(5)52-39(34(47)33(35)41(8)9)55-36-27(16-17-42)19-23(3)28(43)15-13-11-12-14-24(4)50-31(46)20-29(44)37(36)49-10/h11-13,15,17,22-29,32-39,43-44,47-48H,14,16,18-21H2,1-10H3/b12-11+,15-13+/t23-,24-,25-,26+,27+,28+,29-,32+,33-,34-,35-,36+,37+,38+,39+,40-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES
CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Kitasamycin.Approved, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Kitasamycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Kitasamycin.Experimental
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Kitasamycin.Approved, Illicit
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Kitasamycin.Approved, Illicit, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Kitasamycin.Experimental, Investigational
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Kitasamycin.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Atorvastatin.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Kitasamycin.Investigational
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Kitasamycin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Kitasamycin.Approved, Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Kitasamycin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Kitasamycin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Kitasamycin.Approved, Investigational
CerivastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Cerivastatin.Approved, Withdrawn
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Kitasamycin.Approved, Investigational, Withdrawn
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Kitasamycin.Experimental
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Kitasamycin.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Kitasamycin.Experimental
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Kitasamycin.Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Kitasamycin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Kitasamycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Kitasamycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Kitasamycin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Kitasamycin.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Kitasamycin.Experimental
DisopyramideKitasamycin may increase the QTc-prolonging activities of Disopyramide.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Kitasamycin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Kitasamycin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Kitasamycin.Approved
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Kitasamycin.Approved, Illicit
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Kitasamycin.Withdrawn
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Kitasamycin.Approved, Investigational
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Kitasamycin.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Kitasamycin.Experimental
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Kitasamycin.Approved, Illicit
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Kitasamycin.Experimental
LovastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Lovastatin.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Kitasamycin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Kitasamycin.Experimental
MevastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Mevastatin.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Kitasamycin.Approved, Illicit
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Kitasamycin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Kitasamycin.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Kitasamycin.Experimental
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Kitasamycin.Approved, Investigational
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Kitasamycin.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Kitasamycin.Approved
PitavastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Pitavastatin.Approved
PravastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Pravastatin.Approved
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Kitasamycin.Experimental
QuinineThe serum concentration of Quinine can be increased when it is combined with Kitasamycin.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Kitasamycin.Approved, Investigational
RifabutinThe metabolism of Rifabutin can be decreased when combined with Kitasamycin.Approved, Investigational
RifaximinThe metabolism of Rifaximin can be decreased when combined with Kitasamycin.Approved, Investigational
SimvastatinThe risk or severity of rhabdomyolysis can be increased when Kitasamycin is combined with Simvastatin.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Kitasamycin.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Kitasamycin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Kitasamycin is combined with Temsirolimus.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Kitasamycin.Approved, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Kitasamycin.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Kitasamycin.Experimental
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Kitasamycin.Approved, Investigational
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Kitasamycin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Kitasamycin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Kitasamycin.Approved
VincamineThe serum concentration of Vincamine can be increased when it is combined with Kitasamycin.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Kitasamycin.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Kitasamycin.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Kitasamycin.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Kitasamycin.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Kitasamycin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C14056
PubChem Compound
5282322
PubChem Substance
310265197
ChemSpider
4445491
ChEBI
34812
ChEMBL
CHEMBL2106399
Drugs.com
Drugs.com Drug Page
Wikipedia
Kitasamycin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.131 mg/mLALOGPS
logP2.72ALOGPS
logP2.78ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)12.68ChemAxon
pKa (Strongest Basic)7.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area199.98 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity201.88 m3·mol-1ChemAxon
Polarizability83.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Disaccharides / Fatty acid esters / Oxanes / Dicarboxylic acids and derivatives / Tertiary alcohols / Alpha-hydrogen aldehydes / Trialkylamines / Secondary alcohols
show 10 more
Substituents
Aminoglycoside core / Macrolide / Disaccharide / Glycosyl compound / O-glycosyl compound / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Oxane / Alpha-hydrogen aldehyde
show 24 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
macrolide (CHEBI:34812)

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on November 12, 2015 09:53 / Updated on August 02, 2018 07:55